SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brian Malloy who wrote (135)12/1/1999 3:00:00 AM
From: glen  Read Replies (1) of 250
 
Welcome to VaxGen. Your investment objectives are exactly as they should be. The wait should be closer to two years, rather than three, and the FDA can move faster if the results of Phase 3 Trials are favorable. If VaxGen does succeed in obtaining FDA approval, this could be a $200 stock. Their potential target market will be the world's population. This is a company with little hype, and very much under-rated and misunderstood. They have a much better chance of succeeding than most realize.

Regards,
glen
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News